Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 105-110 , April 2011

Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature

Received 15 March 2010 ,Revised 6 June 2010 ,Accepted 19 June 2010.

References 

  1. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  2. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696
  3. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  4. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24:5664–5671
  5. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  6. Docetaxel for the adjuvant treatment of early node-positive breast cancer. Technology appraisal guidance 109. Paclitaxel for the adjuvant treatment of early node-positive breast cancer. Technology appraisal guidance 106. 2006 Guidelines.
  7. Harnett A, Smallwood J, Titshall V, Champion A Guideline Development Group. Diagnosis, treatment of early breast cancer, including locally advanced disease-summary of NICE guidance. BMJ. 2009;338:438
  8. NCCN Clinical Practice Guidelines in Oncology. v.1.2009.
  9. Trudeau M, Eisen A, Messersmith H, et al. Adjuvant taxane therapy for women with early-stage, invasive breast cancer: a clinical practice guideline. CCO 2006 Practice Guideline.
  10. Kataja V, Castiglione M ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;4(Suppl.):10–14
  11. BC Agency 2007 Guidelines.
  12. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8:1073–1079
  13. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–5387
  14. Francis P, Crown J, Di Leo A, et al. BIG 02-98 Collaborative Group Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008;100:121–133
  15. Martín M, Rodríguez-Lescure A, Ruiz A, et al. GEICAM 9906 Study Investigators Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100:805–814
  16. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474–2481
  17. Sparano JA, Wang M, Martino S, Jones , et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–1671
  18. Fountzilas G, Skarlos D, Dafni U, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16:1762–1771
  19. Bianco AR, De Matteis A, Manzione L, et al. Sequential epirubicin–docetaxel–CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. J Clin Oncol. 2006;24:18s
  20. Goldstein LJ, O’Neill A, Sparano JA, Perez , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008;26(25):4092–4099
  21. Ellis P, Barrett-Lee P, Johnson L, et al. TACT Trial Management Group TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373:1681–1692
  22. Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010;28:77–82
  23. Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;(4).
  24. De Laurentiis M, Cancello G, D’Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53
  25. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106:2337–2344
  26. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11:1–144

PII: S0305-7372(10)00107-6

doi: 10.1016/j.ctrv.2010.06.002

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 105-110 , April 2011

Article Tools